·SEC EDGARLow
Torres Denice purchased $99K of SPTX
Torres Denice purchased 5,000 shares of Seaport Therapeutics, Inc. (SPTX) at $19.86 on 2026-11-03.
StockNASDAQ · US · USDHealthcare · Biotechnology
$SPTX
Seaport Therapeutics, Inc.
Seaport Therapeutics is a clinical-stage biopharmaceutical company based in Boston, Massachusetts. It develops medicines for neuropsychiatric conditions, including depression and anxiety disorders, using its Glyph technology platform. The company’s drug candidates are designed for oral use and to avoid first-pass metabolism, with the aim of reducing liver enzyme elevations and other side effects.
AlphAI earnings readThird Quarter 2026 · NOV 2Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical ProgressVerdict: solidRead →
Reads like this one publish minutes after the filing lands on EDGAR. Get them as JSON over the API or inside your AI agent over MCP.
Price · $SPTXvia TradingView
AI sentiment · 7d6 articles
- Bullish
- 4
- Neutral
- 1
- Bearish
- 1
Insider · 30dAll trades →
- Buys
- $99K 1 txs
- Sells
- — 0 txs
Torres Denice1× · $99K
10b5-1 share of filings0%
Top stories · $SPTXMore →
·investing.com
Stifel reiterates Seaport Therapeutics stock rating at buy
Stifel reaffirmed a Buy rating and $30 price target for Seaport Therapeutics (SPTX) after its Q3 update. Analysts' targets range from $28 to $50, with the stock currently at $20.01. The company reported positive GlyphAllo trial results and has $403.8M in cash. Multiple analysts maintain bullish outlooks, citing key upcoming data.
·tradingview.com
Seaport Therapeutics Reports Q3 2026 Net Loss of $26.4 Million and $403.8 Million in Cash
Seaport Therapeutics reported a Q3 2026 net loss of $26.4M, up from $22.5M a year earlier, driven by increased R&D spending. Cash reserves totaled $403.8M, expected to last into 2029. Key clinical updates include positive Phase 1 results for GlyphAllo and the start of a Phase 2a trial for GlyphAgo.
SPTX sentiment & insider activity
Over the past 7 days, AlphAI's AI scored 6 news stories mentioning SPTX (Seaport Therapeutics, Inc.). Coverage has skewed bullish: 4 bullish, 1 neutral, and 1 bearish.
Recent SPTX coverage spans earnings, financial news and insider activity.
In the last 30 days, SPTX insiders filed 1 SEC Form 4 transaction — 1 purchase ($99K) and no sales. The most active reporter was Torres Denice with 1 filing.
What's driving SPTX
The purchase adds insider buying pressure but is modest in size.
Analyst reaffirmation may support modest upside pressure.
Fresh earnings numbers and early‑stage clinical data provide new information that could lift the stock on positive trial outlook while the loss may temper enthusiasm.
The widened loss may prompt short‑term price pressure as investors reassess cash burn.
Earnings beat on a loss may limit upside; investors likely focus on the continued negative EPS.
AlphAI scores every news story that mentions SPTX with an AI model for sentiment and relevance, and aggregates insider trades from Seaport Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
News on $SPTX
Score
Torres Denice purchased $99K of SPTX
Torres Denice purchased 5,000 shares of Seaport Therapeutics, Inc. (SPTX) at $19.86 on 2026-11-03.
Stifel reiterates Seaport Therapeutics stock rating at buy
Stifel reaffirmed a Buy rating and $30 price target for Seaport Therapeutics (SPTX) after its Q3 update. Analysts' targets range from $28 to $50, with the stock currently at $20.01. The company reported positive GlyphAllo trial results and has $403.8M in cash. Multiple analysts maintain bullish outlooks, citing key upcoming data.
Seaport Therapeutics Reports Q3 2026 Net Loss of $26.4 Million and $403.8 Million in Cash
Seaport Therapeutics reported a Q3 2026 net loss of $26.4M, up from $22.5M a year earlier, driven by increased R&D spending. Cash reserves totaled $403.8M, expected to last into 2029. Key clinical updates include positive Phase 1 results for GlyphAllo and the start of a Phase 2a trial for GlyphAgo.
Seaport Therapeutics 3Q 2026: Net loss $26.4M, diluted loss per share $0.49— 10-Q Summary
Seaport Therapeutics reported a net loss of $26.4M in Q3 2026, up $3.9M from the prior year. Diluted loss per share was $0.49, compared to $9.43, due to a higher share count. The company is advancing its pipeline, with key trials expected to report results in 2027 and 2028, and anticipates continued operating losses.
Seaport Therapeutics, Inc. GAAP EPS of -$0.49 beats by $0.09 (SPTX:NASDAQ)
Seaport Therapeutics (SPTX) reported Q3 GAAP EPS of -$0.49, beating estimates by $0.09. The company's earnings highlight its financial performance for the quarter.
Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress
Seaport Therapeutics, Inc. (SPTX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 Seaport Therapeutics Reports Third Quarter 2026 Financial Results and Highlights Recent Corporate and Clinical Progress Announced positive topline data from Phase 1 driving simulation trial of GlyphAllo TM , showing that GlyphAllo did not impair next-morning driving
Seaport Therapeutics, Inc. (SPTX) Posts Phase 1 PK Data Showing 6.8x Bioavailability
Seaport Therapeutics reported Phase 1 data for GlyphAgo, showing 6.8x bioavailability increase and 10x lower variability vs. unmodified agomelatine. Phase 2a for GAD has started, with Phase 2/3 planned for 1H 2027. The data supports the Glyph platform and GAD program, but efficacy and safety data are needed for larger impact.
H.C. Wainwright reiterates Seaport Therapeutics stock rating on trial start
H.C. Wainwright reiterated a Buy rating and $50 price target for Seaport Therapeutics (SPTX) after the first patient was dosed in a Phase 2a trial for GlyphAgo. The stock is currently at $17.93, down 5.4% over the past week. The trial evaluates GlyphAgo in adults with generalized anxiety disorder and sleep disturbance. Seaport expects to report top-line data in early 2028. Analysts highlight the company's strong financial position and clinical-stage pipeline.
Seaport Therapeutics begins phase 2a trial for anxiety drug
Seaport Therapeutics (SPTX) began a Phase 2a trial for GlyphAgo, an anxiety and sleep disorder drug, in Australia. The six-week trial tests two dose levels and aims to report data in early 2028. GlyphAgo showed increased bioavailability in a Phase 1 trial. PureTech Health (PRTC) noted Seaport as a portfolio company.
This Tower Semiconductor Analyst Begins Coverage On A Bullish Note; Here Are Top 5 Initiations For Friday
Mizuho initiated coverage on Tower Semiconductor (TSEM) with an Outperform rating and $300 price target. Other initiations include Precigen (PGEN) with a Buy rating and $12 target, Seaport Therapeutics (SPTX) with a Strong Buy rating and $46 target, PDF Solutions (PDFS) with a Buy rating and $60 target, and CF Industries (CF) with an Outperform rating and $162 target.